It’s incredible. While we were all out there taking care of patients, insurance companies were setting us up to take the blame. Truly awe-inspiring corporate malfeasance.
Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS https://t.co/2Ihsmpo6zj This data, to me has always been a critical question. Recurrence is rare, survival can be affected, and the details matter.
Researchers suggest an algorithm whereby confirmatory HPV mRNA testing is performed in patients where p16 status is not consistent with tumor morphology: https://t.co/mdV7nsgTwB #MedTwitter@SarahLRohde@JShinnmd@Penn_ENT @VUMCPathology
Hot off the presses! Are there differences in functional outcomes between early and late intervention for intubation-related laryngeal injury? https://t.co/81mJuwgqo1